There has been a lot of action on Wall Street today as analysts have weighed in on their favorite stocks. Below are the most notable analyst upgrades and downgrades:
Goldman Sachs Group Inc
Michael Carrier of Bank of America/Merrill Lynch upgraded his rating on Goldman Sachs Group Inc (NYSE:GS) from Neutral to Buy with a $220 price target, representing an almost 22% potential upside from where the stock last closed. The analyst believes there is currently an attractive buying opportunity for Goldman Sachs due to the recent market sell-off. Furthermore, Carrier sees the company as well-positioned to generate growth.
Click here to view Michael Carrier’s rating history and performance.
Piper Jaffray analyst Joshua Schimmer downgraded his rating on MannKind Corporation (NASDAQ:MNKD) from Neutral to Underweight and cut his price target from $4 to $1.50, marking almost a 60% downside from where the stock is currently trading. The analyst’s bearish downgrade stems from “lackluster” Afrezza scrips. He notes, “Unfortunately it sounds to us that while awareness is high and some patient blogs on the internet describe some very exciting and differentiated results, Afrezza is being viewed as a very niche product.”
Click here to view Joshua Schimmer’s rating history and performance.
Tetraphase Pharmaceuticals Inc
Nomura Securities analyst Ian Somaiya downgraded his rating on Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) from Buy to Hold and dramatically slashed his price target from $54 to $10, marking a 77.6% downside from where the stock last closed. The analyst downgraded the stock “following the announcement that the IGNITE-2 Phase III trial of eravacycline failed to reach its primary endpoint of non-inferiority to levofloxacin in complicated urinary tract infection (cUTI) setting, despite previously reported positive results from the trial’s lead-in portion.”
Click here to view Ian Somaiya’s rating history and performance.
Pepco Holdings, Inc.
Paul Ridzon of KeyBanc upgraded his rating on Pepco Holding, Inc. (NYSE:POM) from Sector Weight to Overweight with a price target of $25.50, marking a 12.6% potential upside from where shares last closed. The analyst’s upgrade stems from his belief that the company’s deal with Exelon Corp. will close. He notes, “We believe the market is overly discounting the chances of EXC’s proposed acquisition of POM closing. While the unexpected rejection of the deal by Washington, D.C. presents challenges, we believe they are surmountable.”
Click here to view Paul Ridzon’s rating history and performance.
Yingli Green Energy Hold. Co. Ltd. (ADR)
Roth Capital analyst Philip Shen downgraded his rating on Yingli Green Energy Hold. Co. Ltd (ADR) (NYSE:YGE) from Neutral to Sell with a price target of $0.50, marking a 13.7% potential downside from where the stock last closed. Shen downgraded his rating after the company issued a “weak” third quarter guidance and significantly lowered its 2015 shipment guidance “despite strong market demand.”
Click here to view Philip Shen’s rating history and performance.
Walgreens Boots Alliance Inc
Charles Rhyee of Cowen & Co upgraded his rating on Walgreens Boots Alliance Inc (NASDAQ:WBA) from Market Perform to Outperform and raised his price target from $90 to $104, marking a 15.4% potential upside from where the stock last closed. The analyst cited the recent sell-off as an attractive buying opportunity.
Click here to view Charles Rhyee’s rating history and performance.
E*TRADE Financial Corp
Evercore ISI analyst Chris Allen upgraded his rating on E*TRADE Financial Corp (NASDAQ:ETFC) to Buy with a price target of $33, marking a 21% potential upside from where the stock last closed. The analyst notes that the company has taken a big leap forward in its ongoing capital story following yesterday’s announcement that it will pay down $4.4B in wholesale funding obligations.
Click here to view Chris Allen’s rating history and performance.
Plains GP Holdings LP
Global Hunter analyst Sunil Sibal upgraded his rating on Plains GP Holdings LP (NYSE:PAGP) from Neutral to Accumulate, but lowered his price target from $26 to $23, marking a 19% potential upside from where shares last closed. The analyst’s upgrade is based on valuation, potential accretion from acquisitions, and asset growth.
Click here to view Sunil Sibal’s rating history and performance.